The European Medicines Agency has validated a regulatory submission for arpraziquantel, a potential new treatment for schistosomiasis in young children. 23 January 2023
Fatal cases of acute liver failure reported in patients treated with Zolgensma (onasemnogene abeparvovec) were raised this week at the European Medicines Agency 13 January 2023
A marketing authorization submission for talquetamab - an immunotherapy with the potential to shake up the multiple myeloma market - is now sat on regulators’ d 3 January 2023
As anticipated following a positive decision from its scientific committee, the European Medicines Agency has granted marketing authorization for Pluvicto (vipi 14 December 2022
Following a review, the European Medicines Agency’s (EMA) Emergency Task Force (ETF) has concluded that adapted mRNA bivalent vaccines targeting the original st 7 December 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.